Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares Outstanding
Ratios

Summit Therapeutics (SMMT) Leases (2019 - 2026)

Summit Therapeutics filings provide 8 years of Leases readings, the most recent being $19.4 million for Q1 2026.

  • Quarterly Leases rose 205.43% to $19.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $19.4 million through Mar 2026, up 205.43% year-over-year, with the annual reading at $20.6 million for FY2025, 188.58% up from the prior year.
  • Leases hit $19.4 million in Q1 2026 for Summit Therapeutics, down from $20.6 million in the prior quarter.
  • Across five years, Leases topped out at $20.6 million in Q4 2025 and bottomed at $2.0 million in Q2 2022.
  • Average Leases over 5 years is $7.4 million, with a median of $6.4 million recorded in 2025.
  • The largest annual shift saw Leases soared 246.85% in 2023 before it crashed 36.3% in 2025.
  • Summit Therapeutics' Leases stood at $4.2 million in 2022, then skyrocketed by 40.34% to $5.9 million in 2023, then increased by 21.93% to $7.1 million in 2024, then skyrocketed by 188.58% to $20.6 million in 2025, then dropped by 5.91% to $19.4 million in 2026.
  • Per Business Quant, the three most recent readings for SMMT's Leases are $19.4 million (Q1 2026), $20.6 million (Q4 2025), and $5.4 million (Q3 2025).